Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Vaccines

Free Subscription Articles published in Lancet Retrieve available abstracts of 104 articles: HTML format

Single Articles

September 2026
1. DA ASCENSAO GONCALVES MA, de Morais AF, Pascoal CA, Montefusco-Pereira CV, et al
   Gold standard vaccine policy as a global health signal.
   Lancet. 2026 Sep 4:S0140-6736(26)01698-3. doi: 10.1016/S0140-6736(26)01698.
   PubMed    
   
   
   August 2026
2. HALBROOK M, Merritt S, Hoff NA, Mukadi P, et al
   Bundibugyo virus glycoprotein seroreactivity following recombinant vesicular stomatitis virus-Zaire Ebola virus glycoprotein vaccination in outbreak-affected populations of the Democratic Republic of the Congo: a longitudinal cohort study.
   Lancet. 2026 Aug 25:S0140-6736(26)01608-9. doi: 10.1016/S0140-6736(26)01608.
   PubMed     Abstract available
   
   
   July 2026
3. WIYSONGE CS, Iwu-Jaja C
   The African Medicines Agency: time for integration with the African Vaccine Regulatory Forum.
   Lancet. 2026;408:121-122.
   PubMed    
   
   
   June 2026
4. BLAKNEY AK, Top KA, Cowling BJ, Larson HJ, et al
   Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective.
   Lancet. 2026 Jun 30:S0140-6736(26)00512-X. doi: 10.1016/S0140-6736(26)00512.
   PubMed     Abstract available
   
   
   
5. PORTNOY A, Burger EA
   HPV vaccination and early declines in cervical cancer deaths.
   Lancet. 2026 Jun 17:S0140-6736(26)01024-X. doi: 10.1016/S0140-6736(26)01024.
   PubMed    
   
   
   
6. SASIENI P, Falcaro M
   Cervical cancer mortality trends following HPV vaccination in England, 2001-24: an analysis of population-based mortality data.
   Lancet. 2026 Jun 17:S0140-6736(26)00918-9. doi: 10.1016/S0140-6736(26)00918.
   PubMed     Abstract available
   
   
   
7. MEYER M, Kuzmin IV, Dews EA, Hyde MA, et al
   Single-dose mRNA vaccines against Andes hantavirus.
   Lancet. 2026 Jun 10:S0140-6736(26)01124-4. doi: 10.1016/S0140-6736(26)01124.
   PubMed    
   
   
   
8. WHITEMAN M, Tundang R, Maybarduk P, Abdullah H, et al
   How CEPI can enhance global vaccine equity and transparency.
   Lancet. 2026 Jun 8:S0140-6736(26)01137-2. doi: 10.1016/S0140-6736(26)01137.
   PubMed    
   
   
   May 2026
9. GAYTHORPE KAM, Li X, Shankar M, Hartner AM, et al
   Quantifying relative health impact across Gavi, the Vaccine Alliance's portfolio in 117 countries at the subregional level: a modelling study.
   Lancet. 2026;407:1941-1952.
   PubMed     Abstract available
   
   
   
10. OSEI I, Wutor BM
    Vaccine impact in Gavi-supported countries: balancing evidence with policy needs.
    Lancet. 2026;407:1895-1897.
    PubMed    
    
    
    
11. MWAPASA V, Asante KP, Milligan P, Akech S, et al
    Impact of introducing RTS,S/AS01(E) malaria vaccine on mortality in young children in Ghana, Kenya, and Malawi: an observational evaluation of a cluster-randomised implementation programme.
    Lancet. 2026;407:1796-1808.
    PubMed     Abstract available
    
    
    
12. MCCLOSKEY B, Petersen E, Azhar EI, Zumla A, et al
    Meningococcal B resurgence in the UK: implications for updating global vaccine strategies.
    Lancet. 2026 May 8:S0140-6736(26)00863-9. doi: 10.1016/S0140-6736(26)00863.
    PubMed    
    
    
    
13. BRISSON M, Drolet M, Gingras G, Laprise JF, et al
    Substantial increases in cervical cancer inequalities worldwide without enhanced human papillomavirus vaccination and screening efforts: a global modelling study.
    Lancet. 2026;407:1726-1737.
    PubMed     Abstract available
    
    
    
14. CLIFFORD GM
    HPV vaccine scale-up is key to curb rising cervical cancer inequalities.
    Lancet. 2026;407:1662-1663.
    PubMed    
    
    
    April 2026
15. DU X, Anderson CS
    Off-target benefits of influenza vaccination in cardiovascular disease - Authors' reply.
    Lancet. 2026;407:1600.
    PubMed    
    
    
    
16. FROBERT O, Pedersen IB, Hjelholt AJ, Erikstrup C, et al
    Off-target benefits of influenza vaccination in cardiovascular disease.
    Lancet. 2026;407:1599-1600.
    PubMed    
    
    
    
17. MCLELLAN F
    Amadou Sall: virologist committed to vaccine equity.
    Lancet. 2026;407:1590.
    PubMed    
    
    
    
18. NELSON NP, Ward JW
    Hepatitis A prevention in the USA depends on routine universal childhood vaccination.
    Lancet. 2026 Apr 22:S0140-6736(26)00510-6. doi: 10.1016/S0140-6736(26)00510.
    PubMed    
    
    
    
19. JOHANSEN ND, Seco JP, Martinon-Torres F, Biering-Sorensen T, et al
    Unclear benefits of higher doses of influenza vaccine - Authors' reply.
    Lancet. 2026;407:1426.
    PubMed    
    
    
    
20. FLAHAULT A
    Unclear benefits of higher doses of influenza vaccine.
    Lancet. 2026;407:1425-1426.
    PubMed    
    
    
    January 2026
21. POLLARD AJ, Plotkin S
    A risk to child health: confusion and concern over changes to US vaccine policy.
    Lancet. 2026 Jan 20:S0140-6736(26)00090-5. doi: 10.1016/S0140-6736(26)00090.
    PubMed    
    
    
    
22. KIMATHI D, Juan-Giner A, Bob NS, Orindi B, et al
    Low-dose yellow fever vaccination in infants: a randomised, double-blind, non-inferiority trial.
    Lancet. 2026 Jan 13:S0140-6736(25)02069-0. doi: 10.1016/S0140-6736(25)02069.
    PubMed     Abstract available
    
    
    
23. TURTLE L
    Yellow fever vaccine minimum fractional dosing does not extend to infants.
    Lancet. 2026 Jan 13:S0140-6736(25)02364-5. doi: 10.1016/S0140-6736(25)02364.
    PubMed    
    
    
    
24. PALMIERI C, Tafuri S
    Vaccine hesitancy: an evolving challenge.
    Lancet. 2026 Jan 12:S0140-6736(25)02601-7. doi: 10.1016/S0140-6736(25)02601.
    PubMed    
    
    
    
25. WHITAKER M, Elliott J, Gerard-Ursin I, Cooke GS, et al
    Profiling vaccine attitudes and subsequent uptake in 1.1 million people in England: a nationwide cohort study.
    Lancet. 2026 Jan 12:S0140-6736(25)01912-9. doi: 10.1016/S0140-6736(25)01912.
    PubMed     Abstract available
    
    
    
26. VAN GEERTRUYDEN JP, Lariviere Y, Zola Matuvanga T, Van Damme P, et al
    Ebola and health-care providers: the case for preventive vaccination.
    Lancet. 2026 Jan 12:S0140-6736(25)02459-6. doi: 10.1016/S0140-6736(25)02459.
    PubMed    
    
    
    
27. DWEK RA, Feldmann M, Fotinou C, Zitzmann N, et al
    If vaccines falter, broad-spectrum antivirals provide a global shield.
    Lancet. 2026;407:25-26.
    PubMed    
    
    
    December 2025
28. HAEUSER E, Hay SI, Mosser JF
    Population size and vaccination rates for zero-dose estimates - Authors' reply.
    Lancet. 2025;406:2627-2628.
    PubMed    
    
    
    
29. KUMARI N, Shridevi K, Katkuri S, Subudhi S, et al
    Population size and vaccination rates for zero-dose estimates.
    Lancet. 2025;406:2626-2627.
    PubMed    
    
    
    November 2025
30. YADAV PD, Sahay RR
    Safety and immunogenicity of the Hendra virus recombinant soluble glycoprotein G Nipah virus vaccine in adults.
    Lancet. 2025 Nov 14:S0140-6736(25)02277-9. doi: 10.1016/S0140-6736(25)02277.
    PubMed    
    
    
    
31. FRENCK RW JR, Naficy A, Feser J, Dickey MP, et al
    Safety and immunogenicity of a Nipah virus vaccine (HeV-sG-V) in adults: a single-centre, randomised, observer-blind, placebo-controlled, phase 1 study.
    Lancet. 2025 Nov 14:S0140-6736(25)01390-X. doi: 10.1016/S0140-6736(25)01390.
    PubMed     Abstract available
    
    
    October 2025
32. JOHANSEN ND, Modin D, Pardo-Seco J, Rodriguez-Tenreiro-Sanchez C, et al
    Effectiveness of high-dose influenza vaccine against hospitalisations in older adults (FLUNITY-HD): an individual-level pooled analysis.
    Lancet. 2025 Oct 17:S0140-6736(25)01742-8. doi: 10.1016/S0140-6736(25)01742.
    PubMed     Abstract available
    
    
    
33. DE SANTIS M, Palou Redorta J, Nishiyama H, Krawczynski M, et al
    Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial.
    Lancet. 2025 Oct 17:S0140-6736(25)01897-5. doi: 10.1016/S0140-6736(25)01897.
    PubMed     Abstract available
    
    
    
34. HENDRICK J, Raqib R, Noor Z, Faruque ASG, et al
    Shigellosis.
    Lancet. 2025;406:1508-1519.
    PubMed     Abstract available
    
    
    September 2025
35. KUEHN R, Rahden P, Hussain HS, Karkey A, et al
    Enteric (typhoid and paratyphoid) fever.
    Lancet. 2025;406:1283-1294.
    PubMed     Abstract available
    
    
    August 2025
36. LEE K, Kohler J
    Good governance essential to expanding vaccine capacity and strengthening public trust.
    Lancet. 2025 Aug 29:S0140-6736(25)01681-2. doi: 10.1016/S0140-6736(25)01681.
    PubMed    
    
    
    
37. ANDERSON CS, Hua C, Wang Z, Wang C, et al
    Influenza vaccination to improve outcomes for patients with acute heart failure (PANDA II): a multiregional, seasonal, hospital-based, cluster-randomised, controlled trial in China.
    Lancet. 2025 Aug 28:S0140-6736(25)01485-0. doi: 10.1016/S0140-6736(25)01485.
    PubMed     Abstract available
    
    
    
38. BHATT AS, Vardeny O
    Influenza vaccination in heart failure: a shot worth taking?
    Lancet. 2025 Aug 28:S0140-6736(25)01679-4. doi: 10.1016/S0140-6736(25)01679.
    PubMed    
    
    
    
39. KULKARNI PS, Potey AV, Kapse D, Bhamare C, et al
    Post-exposure prophylaxis regimen of rabies monoclonal antibody and vaccine in category 3 potential exposure patients: a phase 4, open-label, randomised, active-controlled trial.
    Lancet. 2025;406:627-635.
    PubMed     Abstract available
    
    
    
40. WAGNER J
    Respiratory syncytial virus vaccine effectiveness.
    Lancet. 2025;406:599.
    PubMed    
    
    
    
41. PAYNE AB, Mitchell PK, Watts JA, Link-Gelles R, et al
    Respiratory syncytial virus vaccine effectiveness - Authors' reply.
    Lancet. 2025;406:599-600.
    PubMed    
    
    
    July 2025
42. LARSON HJ, Piatek SJ
    A crisis of credibility: the global cost of US vaccine misinformation.
    Lancet. 2025 Jul 30:S0140-6736(25)01495-3. doi: 10.1016/S0140-6736(25)01495.
    PubMed    
    
    
    June 2025
43. FANG H
    Strengthening global routine childhood vaccination.
    Lancet. 2025 Jun 24:S0140-6736(25)01278-4. doi: 10.1016/S0140-6736(25)01278.
    PubMed    
    
    
    
44. 
    Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: a systematic analysis for the Global Burden of Disease Study 2023.
    Lancet. 2025 Jun 24:S0140-6736(25)01037-2. doi: 10.1016/S0140-6736(25)01037.
    PubMed     Abstract available
    
    
    
45. PAIL O, Lin MJ, Anagnostou T, Brown BD, et al
    Cancer vaccines and the future of immunotherapy.
    Lancet. 2025 Jun 17:S0140-6736(25)00553-7. doi: 10.1016/S0140-6736(25)00553.
    PubMed     Abstract available
    
    
    
46. HIRANI K, Rwebembera J, Webb R, Beaton A, et al
    Acute rheumatic fever.
    Lancet. 2025;405:2164-2178.
    PubMed     Abstract available
    
    
    
47. LARSON H
    Vaccination: a changing political, scientific, and personal landscape.
    Lancet. 2025 Jun 5:S0140-6736(25)01193-6. doi: 10.1016/S0140-6736(25)01193.
    PubMed    
    
    
    May 2025
48. ATERE AO, Mustapha FB, Mustapha MJ
    Logistics of the malaria vaccine roll-out in Nigeria.
    Lancet. 2025;405:1815.
    PubMed    
    
    
    April 2025
49. MARQUES ETA, Burke DS
    Safety and immunogenicity of a virus-like particle Chikungunya virus vaccine.
    Lancet. 2025;405:1314-1315.
    PubMed    
    
    
    
50. NDEMBI N, Karuna S, Cowden J, Cagigi A, et al
    Accelerating vaccine development in Africa: lessons from HIV research.
    Lancet. 2025 Apr 10:S0140-6736(25)00564-1. doi: 10.1016/S0140-6736(25)00564.
    PubMed    
    
    
    March 2025
51. RICHARDSON JS, Anderson DM, Mendy J, Tindale LC, et al
    Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: a phase 3, randomised, double-blind, placebo-controlled trial.
    Lancet. 2025 Mar 27:S0140-6736(25)00345-9. doi: 10.1016/S0140-6736(25)00345.
    PubMed     Abstract available
    
    
    
52. TINDALE LC, Richardson JS, Anderson DM, Mendy J, et al
    Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial.
    Lancet. 2025 Mar 27:S0140-6736(25)00372-1. doi: 10.1016/S0140-6736(25)00372.
    PubMed     Abstract available
    
    
    
53. MENSAH AA, Whitaker H, Andrews NJ, Watson CH, et al
    Early impact of RSV vaccination in older adults in England.
    Lancet. 2025 Mar 24:S0140-6736(25)00346-0. doi: 10.1016/S0140-6736(25)00346.
    PubMed    
    
    
    
54. DIALLO F, Haidara FC, Tapia MD, Dominguez Islas CP, et al
    Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, c
    Lancet. 2025 Mar 11:S0140-6736(25)00046-7. doi: 10.1016/S0140-6736(25)00046.
    PubMed     Abstract available
    
    
    
55. ALVES L
    Brazil hopes for new vaccine to combat dengue.
    Lancet. 2025;405:770.
    PubMed    
    
    
    February 2025
56. PRASAD A
    Sarah Blagden: designing vaccines for cancer prevention.
    Lancet. 2025;405:613.
    PubMed    
    
    
    
57. NEUPANE D, Jaiswal LS, Koirala S
    Nepal set to launch historic HPV vaccination programme.
    Lancet. 2025;405:375.
    PubMed    
    
    
    January 2025
58. MUMFORD L, Hogg R, Taylor A, Lanyon P, et al
    Impact of SARS-CoV-2 spike antibody positivity on infection and hospitalisation rates in immunosuppressed populations during the omicron period: the MELODY study.
    Lancet. 2025;405:314-328.
    PubMed     Abstract available
    
    
    
59. DATOO MS, Hill AVS, Beaumont E, Bradley J, et al
    The R21/Matrix-M malaria vaccine: questions remain - Author's reply.
    Lancet. 2025;405:299-301.
    PubMed    
    
    
    
60. AABY P, Bjorkman A, Schapira A, Benn CS, et al
    The R21/Matrix-M malaria vaccine: questions remain.
    Lancet. 2025;405:299.
    PubMed    
    
    
    
61. OBARO S, Mokuolu O, Michelow IC
    The R21/Matrix-M malaria vaccine: questions remain.
    Lancet. 2025;405:299.
    PubMed    
    
    
    
62. LI Y, Liu G
    The R21/Matrix-M malaria vaccine: questions remain.
    Lancet. 2025;405:298-299.
    PubMed    
    
    
    
63. IMPOUMA B, Adidja A, Mboussou F, Cabore J, et al
    Malaria vaccine introduction in Africa: progress and challenges.
    Lancet. 2025 Jan 21:S0140-6736(24)02841-1. doi: 10.1016/S0140-6736(24)02841.
    PubMed    
    
    
    
64. DZAU V, Hatchett R, Bishen S, Kaseya J, et al
    The time for regionalised vaccine manufacturing has arrived.
    Lancet. 2025 Jan 14:S0140-6736(25)00050-9. doi: 10.1016/S0140-6736(25)00050.
    PubMed    
    
    
    December 2024
65. TONY YANG Y
    The perils of RFK Junior's anti-vaccine leadership for public health.
    Lancet. 2024 Dec 18:S0140-6736(24)02603-5. doi: 10.1016/S0140-6736(24)02603.
    PubMed    
    
    
    November 2024
66. INO H, Takimoto Y, Nakazawa E
    Misinformation targeting replicon vaccine recipients: an urgent public health ethical issue.
    Lancet. 2024;404:1922-1923.
    PubMed    
    
    
    October 2024
67. PAYNE AB, Watts JA, Mitchell PK, Dascomb K, et al
    Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis.
    Lancet. 2024;404:1547-1559.
    PubMed     Abstract available
    
    
    
68. BRANDA F, Oh J, Acharya KP, Yon DK, et al
    Human vaccination for highly pathogenic avian influenza.
    Lancet. 2024;404:1518-1519.
    PubMed    
    
    
    
69. BRANCHE AR
    Real-world effectiveness studies of the benefit of RSV vaccines.
    Lancet. 2024;404:1498-1500.
    PubMed    
    
    
    
70. ADEPOJU P
    Rwandan Marburg outbreak sparks vaccine efforts.
    Lancet. 2024;404:1389.
    PubMed    
    
    
    
71. QADRI F, Khanam F, Zhang Y, Biswas PK, et al
    5-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in Bangladeshi children (TyVOID): a cluster randomised trial.
    Lancet. 2024;404:1419-1429.
    PubMed     Abstract available
    
    
    
72. AL-MAMUN F, Mamun MA, Roy N
    Long-term efficacy and public health implications of the Vi-tetanus toxoid conjugate vaccine in Bangladeshi children.
    Lancet. 2024;404:1378-1379.
    PubMed    
    
    
    September 2024
73. PHUYAL S, Acharya KP, Yon DK
    Antibody titres after vaccination: a missing key to rabies control.
    Lancet. 2024;404:1192-1193.
    PubMed    
    
    
    
74. SALEEM SM, Jan SS
    Operationalising the One Health approach for rabies elimination.
    Lancet. 2024;404:1191-1192.
    PubMed    
    
    
    
75. ADEPOJU P
    Vaccination under way as mpox cases continue to rise.
    Lancet. 2024;404:1184.
    PubMed    
    
    
    
76. MAZUR NI, Caballero MT, Nunes MC
    Severe respiratory syncytial virus infection in children: burden, management, and emerging therapies.
    Lancet. 2024;404:1143-1156.
    PubMed     Abstract available
    
    
    
77. WALDMAN R, Steinglass R, Nieburg P
    An urgent case for measles vaccination in Gaza.
    Lancet. 2024 Sep 20:S0140-6736(24)02076-2. doi: 10.1016/S0140-6736(24)02076.
    PubMed    
    
    
    
78. PECENKA C, Sparrow E, Feikin DR, Srikantiah P, et al
    Respiratory syncytial virus vaccination and immunoprophylaxis: realising the potential for protection of young children.
    Lancet. 2024 Sep 6:S0140-6736(24)01699-4. doi: 10.1016/S0140-6736(24)01699.
    PubMed     Abstract available
    
    
    
79. NTUMBA HCK, Mandja BM
    Mpox in eastern Democratic Republic of the Congo: challenges and prospects for vaccination.
    Lancet. 2024 Sep 2:S0140-6736(24)01806-3. doi: 10.1016/S0140-6736(24)01806.
    PubMed    
    
    
    August 2024
80. ZHONG L, Zhao Q, Zeng MS, Zhang X, et al
    Prophylactic vaccines against Epstein-Barr virus.
    Lancet. 2024;404:845.
    PubMed    
    
    
    
81. NEUZIL KM, Patel PD, Ndeketa L, Laurens MB, et al
    Efficacy of typhoid conjugate vaccine in Malawian children - Authors' reply.
    Lancet. 2024;404:748.
    PubMed    
    
    
    
82. OBARO S
    Efficacy of typhoid conjugate vaccine in Malawian children.
    Lancet. 2024;404:747-748.
    PubMed    
    
    
    
83. SCHIFFMAN M, de Sanjose S
    The rational design of cervical cancer prevention strategies.
    Lancet. 2024;404:406-407.
    PubMed    
    
    
    July 2024
84. ADEPOJU P
    African mpox surges show lack of vaccine access.
    Lancet. 2024;404:18.
    PubMed    
    
    
    June 2024
85. LI P, Meng Z, Zhou Z, Zhong Z, et al
    Therapeutic vaccines for Epstein-Barr virus: a way forward.
    Lancet. 2024;403:2779-2780.
    PubMed    
    
    
    
86. HO A, Galgut O, Faustini S, Peters N, et al
    Implications of suboptimal measles immunity in UK health-care workers.
    Lancet. 2024 Jun 26:S0140-6736(24)01011-0. doi: 10.1016/S0140-6736(24)01011.
    PubMed    
    
    
    
87. SAMARASEKERA U
    African vaccine manufacturing scheme to boost production.
    Lancet. 2024;403:2579-2580.
    PubMed    
    
    
    
88. ASHINZE P, Mafua N, Obafemi E
    Nigeria rolls out novel meningitis vaccine.
    Lancet. 2024;403:2373.
    PubMed    
    
    
    May 2024
89. LAXMINARAYAN R, Impalli I, Rangarajan R, Cohn J, et al
    Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance.
    Lancet. 2024 May 20:S0140-6736(24)00878-X. doi: 10.1016/S0140-6736(24)00878.
    PubMed     Abstract available
    
    
    
90. ADAMU AA, Ndwandwe D, Jalo RI, Muhammad ID, et al
    Cofinancing immunisation through national health insurance.
    Lancet. 2024;403:1983-1984.
    PubMed    
    
    
    
91. SHATTOCK AJ, Johnson HC, Sim SY, Carter A, et al
    Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization.
    Lancet. 2024 May 2:S0140-6736(24)00850-X. doi: 10.1016/S0140-6736(24)00850.
    PubMed     Abstract available
    
    
    April 2024
92. COULBORN RM, Danet C, Alsalhani A
    Measles and rubella vaccine microneedle patch: new hope to reach the unreached children.
    Lancet. 2024 Apr 29:S0140-6736(24)00749-9. doi: 10.1016/S0140-6736(24)00749.
    PubMed    
    
    
    
93. ADIGWEME I, Yisa M, Ooko M, Akpalu E, et al
    A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial.
    Lancet. 2024 Apr 29:S0140-6736(24)00532-4. doi: 10.1016/S0140-6736(24)00532.
    PubMed     Abstract available
    
    
    
94. ADEPOJU P
    Moderna stalls on African vaccine manufacturing plans.
    Lancet. 2024;403:1617.
    PubMed    
    
    
    
95. ASANTE KP, Mathanga DP, Milligan P, Akech S, et al
    Feasibility, safety, and impact of the RTS,S/AS01(E) malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi.
    Lancet. 2024 Apr 4:S0140-6736(24)00004-7. doi: 10.1016/S0140-6736(24)00004.
    PubMed     Abstract available
    
    
    
96. DAUBENBERGER CA, Silva JC
    First-generation malaria vaccine successfully implemented in three African countries.
    Lancet. 2024 Apr 4:S0140-6736(23)02892-1. doi: 10.1016/S0140-6736(23)02892.
    PubMed    
    
    
    March 2024
97. RAQIB R
    Bivalent conjugate vaccines for typhoid and paratyphoid fever.
    Lancet. 2024 Mar 28:S0140-6736(24)00461-6. doi: 10.1016/S0140-6736(24)00461.
    PubMed    
    
    
    
98. KULKARNI PS, Potey AV, Bharati S, Kunhihitlu A, et al
    The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, active-controlled, double-blind trial.
    Lancet. 2024 Mar 28:S0140-6736(24)00249-6. doi: 10.1016/S0140-6736(24)00249.
    PubMed     Abstract available
    
    
    
99. BURKI T
    Pivotal tuberculosis vaccine trial begins.
    Lancet. 2024;403:1125.
    PubMed    
    
    
    
100. SHAWE-TAYLOR M, Greenwood D, Hobbs A, Dowgier G, et al
     Divergent performance of vaccines in the UK autumn 2023 COVID-19 booster campaign.
     Lancet. 2024 Mar 11:S0140-6736(24)00316-7. doi: 10.1016/S0140-6736(24)00316.
     PubMed    
     
     
     
101. BURKI T
     The great cholera vaccine shortage.
     Lancet. 2024;403:891-892.
     PubMed    
     
     
     
102. PARHIZ H, Atochina-Vasserman EN, Weissman D
     mRNA-based therapeutics: looking beyond COVID-19 vaccines.
     Lancet. 2024 Mar 7:S0140-6736(23)02444-3. doi: 10.1016/S0140-6736(23)02444.
     PubMed     Abstract available
     
     
     February 2024
103. OCHOGE M, Futa AC, Umesi A, Affleck L, et al
     Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial.
     Lancet. 2024 Feb 22:S0140-6736(23)02844-1. doi: 10.1016/S0140-6736(23)02844.
     PubMed     Abstract available
     
     
     
104. COOPER LV, Blake IM
     First Africa-based clinical trial for novel type 2 oral poliovirus vaccine.
     Lancet. 2024 Feb 22:S0140-6736(24)00053-9. doi: 10.1016/S0140-6736(24)00053.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum